Only four requests for a fast-track drug review were submitted by companies to the European Medicines Agency in the first half of 2022 and none of them were granted.
Accelerated Assessment Requests Fall Flat At EMA
Pharming Awaits Verdict On Leniolisib
Very few companies asked the European Medicines Agency to fast track their drug marketing authorization applications in the first half of this year, and those that did were all turned down.
